News

Sorry, there are no news articles that match your selection.

Information Related to the Voluntary Recall of Infants' Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL December 06, 2018

Tris Pharma recently issued a voluntary recall and an associated press release regarding 3 batches (00717009A, 00717015A, 00717024A) of Infant’s Ibuprofen...

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen December 06, 2018

MONMOUTH JUNCTION, NJ, December 05, 2018 / PRNewswire/ -– Monmouth Junction, NJ, Tris Pharma, Inc. has voluntarily recalled three (3) lots of Infants’...

Tris Pharma Presents Clinical Data for DYANAVEL® XR (amphetamine) at the 2018 Neuroscience Education Institute (NEI) Congress November 12, 2018

The trial of children 6 to 12 years with ADHD demonstrated that DYANAVEL XR was effective in reducing symptoms of ADHD at 4 hours with a clinical onset at 1...

Aytu BioScience Enters $3 Billion Cough and Cold Market and Expands Primary Care Portfolio, with Exclusive U.S. Licensing of Revenue-Generating, FDA-Approved Antitussive Tuzistra® XR November 05, 2018

ENGLEWOOD, CO / ACCESSWIRE / November 5, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization...

Tris Pharma Presents Results from Two Clinical Studies on Dyanavel® XR at the Largest Annual Meeting of Child and Adolescent Psychiatrists October 25, 2018

MONMOUTH JUNCTION, NJ, October 24, 2018 / PRNewswire/ - Tris Pharma, Inc. (Tris), a biopharmaceutical company focused on developing innovative products that...

Tris Pharma Announces Hiring of Chief Commercial Officer October 09, 2018

MONMOUTH JUNCTION, NJ, October 10, 2018 / PRNewswire/ - Tris Pharma, Inc. (Tris), a pharmaceutical company focused on developing innovative...

Tris Pharma Expands ADHD Portfolio with Acquisition of NextWave Pharmaceuticals September 24, 2018

MONMOUTH JUNCTION, NJ, September 25, 2018 / PRNewswire/ - Tris Pharma, Inc. (Tris), a pharmaceutical company focused on developing innovative...

Tris Pharma Announces Hiring of New Vice President of Quality & Compliance August 26, 2018

MONMOUTH JUNCTION, NJ, August 27, 2018 / PRNewswire/ - Tris Pharma, Inc. (Tris), a pharmaceutical company focused on developing innovative technology-based...

Tris Pharma’s Results from a Laboratory Classroom Study of DYANAVEL® XR in Children with ADHD Featured at APSARD February 08, 2017

MONMOUTH JUNCTION, N.J., February 9, 2017 - Tris Pharma, Inc. (“Tris”) announced that results from a laboratory classroom study of DYANAVEL XR...

FDA accepts CCP-08 NDA for full review December 20, 2016

Vernalis plc and Tris Pharma, Inc. (“Tris”) are pleased to announce that the U.S. Food and Drug Administration (“FDA”) has accepted the CCP-08 New...

FDA accepts CCP-07 NDA for full review September 05, 2016

Vernalis plc and Tris Pharma, Inc. ("Tris") are pleased to announce that the U.S. Food and Drug Administration ("FDA") has accepted the CCP-07 New Drug...

Tris Pharma Announces the Launch of DYANAVEL™ XR (amphetamine) Extended-release Oral Suspension, CII for the Treatment of Children with ADHD April 18, 2016

MONMOUTH JUNCTION, N.J., April 19, 2016 - Tris Pharma, Inc. ("Tris") announces today the launch of DYANAVEL™ XR (amphetamine), CII, the...

Tris Pharma Announces First Ever FDA-Approved Extended-Release Chewable Tablet December 15, 2015

MONMOUTH JUNCTION, NJ, December 16, 2015 / PRNewswire/ - Tris Pharma, Inc. ("Tris") is pleased to announce that the U.S. Food and Drug Administration ("FDA")...

Pfizer Receives U.S. FDA Approval of New QuilliChew ER (methylphenidate hydrochloride) extended-release chewable tablets CII December 06, 2015

NEW YORK, N.Y., December 7 -- Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved QuilliChew ER chewable tablets. Pfizer...

Tris Pharma Receives FDA Approval of Dyanavel XR (amphetamine) CII as Once-Daily Liquid for Treatment of ADHD in Children October 19, 2015

MONMOUTH JUNCTION, N.J., October 20, 2015 -- Tris Pharma, Inc. ("Tris") announced that the U.S. Food and Drug Administration ("FDA") has approved...

Tris Pharma Launches Generic Tussionex® as Par’s Rights Expire September 30, 2015

Monmouth Junction, N.J., Oct. 1, 2015 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery...

Vernalis PLC launches Tuzistra XR (codeine polistirex and chlorpheniramine polistirex) for cough relief with 12-hour dosing September 07, 2015

Vernalis plc (LSE: VER) and Tris Pharma today announce that Tuzistra™ XR (codeine polistirex and chlorpheniramine polistirex), extended-release oral...

FSC Pediatrics Launches Karbinal™ ER (carbinoxamine maleate) For the Symptomatic Treatment of Seasonal and Perennial Allergic Rhinitis for Children August 12, 2015

CHARLOTTE, N.C., August 13, 2015; - FSC Pediatrics announced today the launch of Karbinal™ ER, the only 1st generation extended-release oral...

Tris Pharma and Pfizer Consumer Healthcare Enter Into Agreement to Commercialize 12-Hour Extended Release Dextromethorphan Cough Syrup under the Robitussin® Brand June 28, 2015

MONMOUTH JUNCTION, N.J., June 29, 2015; - Tris Pharma, Inc. ("Tris") today announced that it has entered into a license, supply, and distribution agreement...

Tris Pharma Announces the FDA Acceptance of NDA for Dyanavel XR May 20, 2015

MONMOUTH JUNCTION, N.J., May 21, 2015; - Tris Pharma, Inc. ("Tris") announced that U.S. Food and Drug Administration ("FDA") has accepted for review its...

Vernalis and Tris Pharma receive FDA approval of NDA for Tuzistra™ XR April 30, 2015

MONMOUTH JUNCTION, N.J., May 1, 2015; - Vernalis plc and Tris Pharma Inc. today announce that the U.S. Food and Drug Administration (FDA) has approved the...

FDA accepts Tuzistra™ XR (CCP-01) NDA for full review September 14, 2014

MONMOUTH JUNCTION, N.J., September 15, 2014; - Vernalis plc and Tris Pharma, Inc. ("Tris") are pleased to announce that the U.S. Food and Drug...

Tris Pharma Receives NJBIA Award for Excellence August 26, 2014

MONMOUTH JUNCTION, N.J., August 27, 2014; - Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies,...

Third Product in Vernalis’ Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept July 21, 2014

Vernalis plc and Tris Pharma, Inc. today announce the achievement of proof-of-concept (POC) for CCP-08, the third programme to achieve this milestone in their...

Submission of Tuzistra XR (CCP-01) NDA to FDA June 29, 2014

Vernalis plc and Tris Pharma, Inc. ("Tris") are pleased to announce that a New Drug Application ("NDA") has been submitted to the U.S. Food and Drug...

Second Product in Vernalis’ Cough Cold Pipeline Achieves Proof-of-Concept March 31, 2014

Vernalis plc and Tris Pharma, Inc. today announce the achievement of proof-of-concept (POC) for CCP-07, the second programme to achieve this milestone in...

Vernalis Announces Successful Completion of Second Pivotal Bioavailability Study with First Cough Cold Product, CCP-01 January 31, 2014

Vernalis plc today announces successful completion of the second and final CCP-01 pivotal comparative bioavailability study. This positive multi-dose study...

Tris Pharma and FSC Laboratories Sign Definitive Commercialization Agreement for Karbinal™ ER (carbinoxamine maleate) Extended-Release Oral Suspension September 03, 2013

MONMOUTH JUNCTION, N.J. & CHARLOTTE, N.C., September 4, 2013 -- Tris Pharma, Inc. and FSC Laboratories, Inc. today announced the signing of a definitive...

Tris Pharma’s Generic Pharmaceuticals Business Launches Dextroamphetamine Sulfate Oral Solution July 09, 2013

MONMOUTH JUNCTION, N.J., July 10, 2013 - Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today...

Tris Pharma Hires President for Generic Pharmaceuticals Business June 19, 2013

MONMOUTH JUNCTION, N.J., June 20, 2013 - Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today...

Tris Pharma’s Ketan Mehta Among Ernst & Young Entrepreneur Of The Year® 2013 Finalists in New Jersey May 01, 2013

MONMOUTH JUNCTION, N.J., May 2, 2013 - Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today...

FDA Approves Tris Pharma’s New Drug Application for Karbinal ER (carbinoxamine maleate) Extended-release Oral Suspension April 02, 2013

MONMOUTH JUNCTION, N.J., April 3, 2013 -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today...

First Product in Tris Pharma’s Collaboration with Vernalis Achieves Proof-of-Concept, Triggering Milestone Payment to Tris March 10, 2013

MONMOUTH JUNCTION, N.J., March 11, 2013 -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies,...

Pfizer Announces Availability Of Quillivant XR (methylphenidate hydrochloride) CII For Extended-Release Oral Suspension In The United States January 13, 2013

NEW YORK, N.Y., January 14 - Pfizer Inc. (NYSE: PFE) today announced that Quillivant XR™ (methylphenidate hydrochloride) CII for extended-release oral...

Pfizer To Acquire NextWave Pharmaceuticals, Inc. October 21, 2012

NEW YORK--(BUSINESS WIRE[1])--Pfizer Inc [2]. (NYSE: PFE) today announced its intention to acquire NextWave Pharmaceuticals [3], a privately held, specialty...

Perrigo and Tris Pharma launch store brand version of Delsym® August 26, 2012

ALLEGAN, Mich. and MONMOUTH JUNCTION, NJ – August 27, 2012 – Perrigo Company (Nasdaq: PRGO;TASE) and Tris Pharma, Inc. today announced the commercial...

Tris Pharma Expands Manufacturing Capacity and Strengthens Supply Chain to Support New and Pending Approvals July 10, 2012

MONMOUTH JUNCTION, N.J., July 11; /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company with fully integrated commercial manufacturing and drug...

Tris Pharma Announces Approval of First-Ever Generic to Delsym® Dextromethorphan Polistirex Extended-Release Suspension May 30, 2012

MONMOUTH JUNCTION, N.J., May 31; /PRNewswire/ -- Tris Pharma, a technology driven specialty pharmaceutical company announced today that the US Food and Drug...

Perrigo announces FDA final approval of Tris Pharma’s Dextromethorphan Polistirex extended-release oral Suspension May 29, 2012

ALLEGAN, Mich. – May 30, 2012 – Perrigo Company (Nasdaq: PRGO;TASE) today announced that the U.S. Food and Drug Administration has granted final approval...

Vernalis and Tris Pharma announce collaboration to develop and commercialize novel products for the US prescription cough/cold market February 05, 2012

Vernalis plc (Vernalis), a UK development stage pharmaceutical company listed on the London Stock Exchange (LSE:VER) and Tris Pharma Inc (Tris) a privately...

Tris Pharma Announces US Patent Grant Covering Platform Technology January 05, 2012

MONMOUTH JUNCTION, N.J., January 6; /PRNewswire/ -- Tris Pharma, an emerging specialty pharmaceutical company announced the US grant of its core technology...